An August study published in the JAMA Health Forum found that between 2008 and 2021, of the 146 drugs receiving fast-tracked approval from the FDA, 61 percent were shown to have low therapeutic value.
61% of drugs receiving fast-tracked FDA approval shown to have low therapeutic value
